1. Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer
- Author
-
Xiaochen Wang, Lifang Yao, Jinlan Shan, Jian Wang, Shizhen Zhang, Xingchang Ren, Jingjing Wu, Zujian Hu, Lirong Chen, and Rui Lei
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,high mobility group A1 ,body mass index ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,breast cancer ,Internal medicine ,medicine ,Risk of mortality ,Oncogene ,Proportional hazards model ,business.industry ,Cancer ,Articles ,medicine.disease ,Molecular medicine ,030104 developmental biology ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,biomarker ,prognosis ,business ,Body mass index - Abstract
The high mobility group A1 (HMGA1) protein is associated with poor prognosis in patients with a wide range of cancers. However, the affect of HMGA1 on the risk of mortality from breast cancer (BC) has not been fully characterized. In the present retrospective multiple center study, the HMGA1 expression level was determined by performing immunohistochemistry on surgical tissue samples of 273 BC specimens from the Second Affiliated Hospital of Zhejiang University (Zhejiang, China) and 310 BCs from the National Engineering Center for Biochip (Shanghai, China). Kaplan-Meier analysis and Cox proportional hazard model were employed to analyze the survivability. HMGA1 expression was significantly associated with tumor histological degree and body mass index (BMI). However, HMGA1 expression showed no prognostic value in patients with BC. Combined evaluation of HMGA1 expression and high BMI (≥24 kg/m2) predicted worse overall survival of BC. Therefore, HMGA1 and BMI were considered to serve synergistic roles in the development and progression of BC, and combined evaluation of HMGA1 expression and high BMI may be an effective marker in predicting poor prognosis of BC patients.
- Published
- 2016